4//SEC Filing
GRAINGER DAVID J 4
Accession 0001847903-22-000067
CIK 0001847903other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 5:04 PM ET
Size
8.9 KB
Accession
0001847903-22-000067
Insider Transaction Report
Form 4
GRAINGER DAVID J
Chief Innovation Officer
Transactions
- Sale
Ordinary Shares
2022-10-03$3.95/sh−2,853$11,270→ 908,575 total - Sale
Ordinary Shares
2022-09-30$4.07/sh−2,328$9,469→ 911,428 total
Holdings
- 27,500(indirect: See footnote)
Ordinary Shares
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted share units and do not represent discretionary trades by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.765 to $4.0499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
Documents
Issuer
Centessa Pharmaceuticals plc
CIK 0001847903
Entity typeother
Related Parties
1- filerCIK 0001887115
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 5:04 PM ET
- Size
- 8.9 KB